87 related articles for article (PubMed ID: 21922393)
21. Update on clinical role of tamoxifen.
Benson JR; Pitsinis V
Curr Opin Obstet Gynecol; 2003 Feb; 15(1):13-23. PubMed ID: 12544497
[TBL] [Abstract][Full Text] [Related]
22. Can quantifying hormone receptor levels guide the choice of adjuvant endocrine therapy for breast cancer?
Mackey JR
J Clin Oncol; 2011 Apr; 29(12):1504-6. PubMed ID: 21422423
[No Abstract] [Full Text] [Related]
23. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Winer EP; Hudis C; Burstein HJ; Wolff AC; Pritchard KI; Ingle JN; Chlebowski RT; Gelber R; Edge SB; Gralow J; Cobleigh MA; Mamounas EP; Goldstein LJ; Whelan TJ; Powles TJ; Bryant J; Perkins C; Perotti J; Braun S; Langer AS; Browman GP; Somerfield MR
J Clin Oncol; 2005 Jan; 23(3):619-29. PubMed ID: 15545664
[TBL] [Abstract][Full Text] [Related]
24. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
25. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
Cataliotti L; Buzdar AU; Noguchi S; Bines J; Takatsuka Y; Petrakova K; Dube P; de Oliveira CT
Cancer; 2006 May; 106(10):2095-103. PubMed ID: 16598749
[TBL] [Abstract][Full Text] [Related]
26. Estrogen deprivation therapy and colon cancer risk in breast cancer patients.
Malaka DO; Olopade OI
Breast J; 2010; 16(1):110-2. PubMed ID: 19929891
[No Abstract] [Full Text] [Related]
27. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
Dowsett M; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G; Smith IE
J Clin Oncol; 2005 Apr; 23(11):2477-92. PubMed ID: 15767642
[TBL] [Abstract][Full Text] [Related]
28. Management of breast cancer in very young women.
Freedman RA; Partridge AH
Breast; 2013 Aug; 22 Suppl 2():S176-9. PubMed ID: 24074783
[TBL] [Abstract][Full Text] [Related]
29. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
[TBL] [Abstract][Full Text] [Related]
30. Targeting adjuvant chemotherapy: a good idea that needs to be proven!
Hayes DF
J Clin Oncol; 2012 Apr; 30(12):1264-7. PubMed ID: 22355050
[No Abstract] [Full Text] [Related]
31. Adjuvant hormonal therapy.
Tamaki Y; Miyoshi Y; Noguchi S
Breast Cancer; 2002; 9(3):185-9. PubMed ID: 12185327
[TBL] [Abstract][Full Text] [Related]
32. The continued evidence from overviews: what is the clinical utility?
Turner N; Biganzoli L; Malorni L; Migliaccio I; Moretti E; Pestrin M; Sanna G; Siclari O; Di Leo A
Breast; 2013 Aug; 22 Suppl 2():S8-11. PubMed ID: 24074798
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant therapy for breast cancer: practical lessons from the early breast cancer trialists' collaborative group.
Hudis CA; Dang CT
Breast Dis; 2004; 21():3-13. PubMed ID: 15687717
[No Abstract] [Full Text] [Related]
34. Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?
van Dam PA; van Dam VC; Altintas S; Papadimitriou K; Rolfo C; Trinh XB
Eur J Surg Oncol; 2016 Mar; 42(3):333-42. PubMed ID: 26776766
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic significance of hormone receptor positivity in patients with HER-2 positive breast cancer.
Kolarova I; Vanasek J; Odrazka K; Melichar B; Ryska A; Petera J; Vosmik M; Dolezel M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2019 Dec; 163(4):285-292. PubMed ID: 31831888
[TBL] [Abstract][Full Text] [Related]
36. From genome to bedside: are we lost in translation?
Hayes DF
Breast; 2013 Aug; 22 Suppl 2():S22-6. PubMed ID: 24074786
[TBL] [Abstract][Full Text] [Related]
37. Endocrine therapy of breast cancer.
Goldhirsch A; Colleoni M; Gelber RD
Ann Oncol; 2002; 13 Suppl 4():61-8. PubMed ID: 12401668
[No Abstract] [Full Text] [Related]
38. Patients with triple negative breast cancer: is there an optimal adjuvant treatment?
Burstein HJ
Breast; 2013 Aug; 22 Suppl 2():S147-8. PubMed ID: 24074776
[No Abstract] [Full Text] [Related]
39. Who benefits from hormone therapy?
Toi M; Iino Y
Breast Cancer; 2006; 13(2):117-22. PubMed ID: 16755104
[TBL] [Abstract][Full Text] [Related]
40. Management recommendations for adjuvant systemic breast cancer therapy.
Perez EA
Breast Dis; 2004; 21():15-21. PubMed ID: 15687718
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]